Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

The common forms of type 2 diabetes are caused by a constellation of genetic and epigenetic factors and molecular changes related to diet; lifestyle, including lack of exercise and sleep; ...

Overweight and obesity pose significant health risks, including an increased likelihood of developing diabetes, cardiovascular disease, and cancer. Researchers are seeking practical ways to promote ...

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC. New research from the ...

Preclinical experiments and an ongoing phase 1 trial suggest that RES-010 may complement and enhance the efficacy of ...

Higher activity of PGC-1α enables brown fat cells in females to achieve thermogenic activity and energy expenditure compared to males, reveals a study conducted in Japan. This research demonstrates ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This ...

Over the past several decades, it has become increasingly evident that many causes of non-communicable diseases (NCD), also known as lifestyle diseases, originate early in life. NCDs include obesity, ...